Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Ascites market is undergoing unprecedented changes which are driven by a myriad of factors which include growing incidence of liver cirrhosis, improvement in treatment options and an ulcerate aging population. Ascites, edema of the abdominal cavity due to the accumulation of unreasonable amount of fluid, is usually triggered by disorders of the liver diseases, especially cirrhosis. The ascension of liver cirrhosis, which has a plethora of factors including alcohol, viral hepatitis and non-alcoholic fatty liver disease, is the core of the market behavior of the Ascites market.
Progress in the treatment options is indeed a key parameter in this marketplace. Management of Ascites manifests in two ways: managing the liver condition that caused the accumulation and managing the per se fluid build-up. Among conventional therapies, diuretics, therapeutic paracentesis, and albumin infusions are some effective tools, whereas novel interventions are starting to appear. Developments of transjugular intrahepatic portosystemic shunts (TIPS) procedures and peritoneovenous shunts illustrated that they have the ability to deal with ascites issues, and new arena for market growth was thus created.
As a result of an aging world population, the rates of ascent are continually growing. With the aging process, the probability of being exposed to chronic liver diseases is also increasing in individuals and the probability of Ascites is also higher. One of the key trends linked to the increasing prevalence of Ascites is that developed countries are getting older. Older population becomes another reason for good management of Ascites diseases.
Differences between the healthcare structure and the disease burden in certain regions provide the basis for the regional patterns of the Ascites Market. Countries with developed health care systems and long-standing know-how in healthcare are most likely to integrate the first generation of state-of-the-art treatment options and technologies. Consequently, the emergence economies are expected to have gains in addition with gradual development of awareness, affordability, and access to advanced Ascites management that will also contribute to expansion of the market.
The competitive arena of Ascites sector is marked by pharma brands and manufacturers of the medical device industry aiming at innovating and getting a better cure. Research and development activities seek to refine current therapeutics, develop entirely new medications, and come up with less invasive diagnostic procedures. Partnerships with healthcare professionals such as hepatologists and gastroenterologists are frequently used best practices of giving access to clinical needs and increasing the product’s benefits.
The general Ascites management process is a complicated task to perform because it is also associated with various complications, such as renal dysfunction and infections. Overcoming these hurdles necessitates a 'whole-of-governmental' approach that entails the multidisciplinary of a healthcare team as well as the development of interventional treatment models.
Ascites Market Highlights:
Global Ascites Market Overview
The Ascites Market Size was valued at USD 1.29 Billion in 2023. The global ascites industry is projected to grow from USD 1.36 Billion in 2024 to USD 2.41 Billion by 2032, exhibiting a CAGR of 3.89% during the forecast period (2024 - 2032).
Ascites are abnormal fluid that is gathered in the intestinal chamber. Ascites most generally make the occurrence of liver cirrhosis. Its presence is a gateway to high blood pressure. However, some minorly found factors of ascites are heart failure, kidney failure, cancers, and pancreas infection.
Further, when the ascites become malignant, they become the principal cause of ovarian cancer. Moreover, Malignancy connected to ascites can also notice in tumours of the breast, lung, pancreas, gastric, and liver. The physical examination can track ascites when the volume is higher than 1.5 l. However, ultrasound and CT scans are recommended when the fluid gathering is smaller.
In Jan 2024,Sequana Medical announced the substantive review of alfa pump’s Premarket Approval (PMA) application by the United States Food and Drug Administration (US FDA). The company projects an FDA approval in H2 2024.
In December 2023,OCE-205 was granted Orphan Drug Designation (ODD) by the US FDA for ascites treatment not involving cancer except for etiologies .
In 2023, Astellas Pharma revealed that it had executed a licensing deal with Mirati Therapeutics on the development and commercialisation of a drug candidate indicated for ascites. This collaboration is expected to leverage both companies’ capabilities and take the field ahead significantly.
In 2022, Gilead Sciences declared that they had completed the acquisition of Principia Biopharma, a company which is developing new ascites treatment. Gilead Science’s resources and expertise are expected to accelerate the market introduction of this treatment, giving hope to patients with this difficult condition.
In June 2021,Johnson & Johnson entered into a partnership with Arbutus Biopharma in order to develop and commercialize an ascites drug candidate, according to an announcement made on their website . Both companies have combined their assets under this agreement, which should result in significant market advancements due to joint efforts.
In March 2020,Novartis submitted its New Drug Application (NDA) for its ascites drug candidate to FDA. This marks a major progression towards the development of a therapy against this malady.
COVID-19 Analysis
The scattering cases of the coronavirus pandemic have a great jolt on life around the world. The most affected by COVID-19 are the two departments, i.e., health and economy. Therefore, they have experienced a period of decreased economic activity and depression. The only solution to this crooked situation is to make a blueprint amid this epidemic. According to the report, companies shall aid in the future Ascites market.
Ascites Market Trends
Market Drivers
In fact, the increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer are the major drivers thrusting the Ascites Market growth. For example, a study shown in the Canadian Journal of Gastroenterology and Hepatology in 2016 describes that almost 75% of Cirrhosis ascites patients are brought to hospitals. Furthermore, in the European Region, Cirrhosis for ascites is found rigorously.
Restrain
However, the rigid ground rules and problems connected with Ascites treatment, such as interior bleeding after paracentesis treatment and vulnerability to radiation in chemotherapy, may constrain the outgrowth of the Market till the forecast period. For example, research in Experimental and Molecular Medicine in 2017 discussed that the non-malignant liver tissues could also catalyze envenomed due to high radiation. Thus, it will take less the course of therapy, and most importantly, it can create chronic ramifications such as late fibrosis.
Opportunities
There are many opportunities expected in Market during the forecast period. The main emphasis will be given to the improvement of the capacity to persuade the tests are delivering a greater impact on the opportunities for the market.
Challenges
Challenges are there in lowering the radiations created by chemotherapy. Also, the complications accompanied by ascites treatment can restrain the market's growth.
Cumulative Analysis
The key driver, the rising cases of Cirrhosis for ascites, will propel the market's growth as suggested in the Ascites Market forecast. For example, in the American Cancer Society Report in 2018, it is reported that due to cancer, 609,640 deaths happened. In 2016 Nano Antibiotics got LAT pharma LLC. Moreover, it is a popular biotechnology company that makes new medications to battle against the overpowering problem of Cirrhosis.
Value Chain Analysis
The increasing Ascites Market because of the rising cases of malignant due to ascites and the introduction of new medicines in biotechnology are some assertive prospects. Basically, the demand for medicines and Diagnoses will increase more in the future and can mutinously improve the market's value chain.
Ascites Market Segment Insights
The Ascites Market splintered into types of Diagnosis, Treatment and clients. Moreover, the development among these segments will help you anatomize recess resources of excrescency. So, you can make your game plans to approach the Ascites Market trend and rule on your quick act or practice of employing your strategies on the areas you can distinct target market.
Ascites Types Insights
According to types, the market is divided into transudative ascites and exudates ascites.
Ascites Diagnosis Insights
However, depending on the diagnosis, the Ascites Market size is divided into ultrasound, CT scan, MRI, blood test, laparoscopy, angiography, etc.
Ascites Treatment Insights
Besides, depending on treatment, it is portioned into medication, paracentesis, surgery, etc. Again, medication has various segments: diuretics, special nutrition, and others.
Ascites Route of Administration Insights
Oral, parental and others are the route of administration segment of Ascites Market. Based on clients, the market splintered into hospitals, specialty clinics, home care, and more. However, the hospital and clinic segment rationalized for Ascites Market revenue of USD 838.4 million.
Ascites Allotment Channel Insights
Moreover, depending on the allotment channel, there are hospital pharmacies, retail pharmacies, online pharmacies and more in the market.
Ascites Regional Insights
So, the regional analysis of the Ascites Market is mainly based on the market size information known from the country.
Consequently, according to Ascites Market Research, America, Europe, Asia Pacific, the Middle East, and Africa are the countries covering this market.
To illustrate, North America holds the largest Ascites Market share because all the main product manufacturers are from here. Furthermore, they have high research and development skills and aced professionals and health care lay.
Besides, Europe holds the second largest market because of their increasing liver damage and cancer cases.
However, according to the Ascites Market forecast, Asia Pacific will hold the largest market in the future years. It will happen because the Asia Pacific has leviathan development opportunities of Market.
Moreover, because of being a county full of poverty and fewer development opportunities, the Middle East and Africa hold the least market of Ascites.
Competitive Landscape
The competitive landscape of Market provides details about a competitor. Additionally, some of the game plans followed by the key players are creativity, output evolution, obtainment and progress.
Some substantive key players in Ascites Market are:
- Square Medical NV of Switzerland
- BioVie Inc. of the US
- PharmaCyte of US
- Fresenius SE & Co. KGaA of Germany
- BD of US
- GI Supply of US
- Medtronic of Ireland
Recent developments
- BIV201 BioVie Inc. got FDA fast-track denotation in December 2017.
- In addition, Fresenius & Co and KGaA far-flung their branches in Mihla, Germany, and for this, they shell out USD 11.78 million. It happened in December 2017.
- Moreover, in April 2017, BD cultivated CD Bard Inc. for the expansion of its branches of the oncology and surgery segment. They outlaid almost USD 24 billion for this venture.
Report Overview
The report overview of Ascites Market consists:
- Market Overview
- COVID-19 Analysis
- Various Market Dynamics
- Value Chain Analysis
- Market Segmentation
- Regional Segmentation
- Competitive Landscape analysis
- Recent Development
Ascites Market Segmentation
Ascites Types Outlook
- Transudative Ascites
- Exudate Ascites
Ascites Diagnosis Outlook
Ascites Treatment Outlook
- Surgeries
Ascites End-users Outlook
- Preface
- Hospitals and health clinics
- Nomadic surgical centre
- Diagnosis centre
Ascites Regional Outlook
America
- North America
- South America
Europe
- Western Europe
- Eastern Europe
Asia Pacific
- China
- Japan
- India
- Australia
The Middle East and Africa
-
Middle East
-
UAE
-
Oman
-
Rest of the Middle East
-
Africa
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
